PTEN and cancer: The treatment of non-resistant cancer cells with these exosomes confers therapeutic resistance to several agents, such as 5-fluorouracil, oxaliplatin, gemcitabine, and sorafenib, owing to the downregulation of PTEN and the activation of PI3K/Akt pathways [180] (Figure 3).